Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$11.02
+1.3%
$11.52
$8.08
$18.23
$380.60M0.82822,601 shs332,243 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$2.37
-3.7%
$1.68
$1.30
$7.55
$130.73M1.382.27 million shs1.20 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$24.09
-1.6%
$29.09
$23.15
$79.96
$9.52B1.839.44 million shs8.27 million shs
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$41.64
-1.9%
$36.77
$5.21
$46.58
$363.63M1.2948,980 shs34,353 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
+1.29%-0.90%+0.82%-31.43%+3.57%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-3.66%+20.92%+64.58%+16.75%-66.76%
Moderna, Inc. stock logo
MRNA
Moderna
-1.55%-11.17%-25.07%-9.30%-69.26%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-1.89%-7.47%+15.70%+57.73%+4,163,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
3.1387 of 5 stars
3.52.00.00.03.12.51.3
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
4.0143 of 5 stars
3.34.00.04.42.70.00.6
Moderna, Inc. stock logo
MRNA
Moderna
4.5915 of 5 stars
4.02.00.04.62.72.51.3
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
2.2706 of 5 stars
3.50.00.00.02.82.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
3.00
Buy$24.50122.32% Upside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.60
Moderate Buy$8.80271.31% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$42.8878.01% Upside
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
3.00
Buy$55.0032.08% Upside

Current Analyst Ratings Breakdown

Latest INO, MRNA, DCTH, and SNWV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$18.00 ➝ $15.00
8/22/2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$54.00 ➝ $55.00
8/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.00
8/7/2025
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$29.00 ➝ $31.00
8/4/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$40.00 ➝ $31.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$32.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$26.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$32.00
7/29/2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$49.00
7/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$26.00 ➝ $25.00
(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$37.21M10.36N/AN/A$3.00 per share3.67
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$182.34K690.75N/AN/A$0.54 per share4.39
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B2.90N/AN/A$24.16 per share1.00
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$39.19M9.10N/AN/A($1.72) per share-24.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
-$26.39M$0.05220.40N/AN/A3.18%6.91%5.80%11/14/2025 (Estimated)
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$107.25M-$2.61N/AN/AN/AN/A-163.32%-96.41%11/13/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-$31.37M-$8.25N/AN/A-97.03%N/A-135.15%N/A

Latest INO, MRNA, DCTH, and SNWV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.63-$0.61+$0.02-$0.61$0.01 millionN/A
8/8/2025Q2 2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-$0.09$0.01+$0.10$0.01$10.14 million$10.16 million
8/6/2025Q2 2025
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$0.02$0.07+$0.05$0.07$22.84 million$24.16 million
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/A
10.88
9.87
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
1.66
1.66
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/A
0.43
0.31

Institutional Ownership

CompanyInstitutional Ownership
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
61.12%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
42.53%

Insider Ownership

CompanyInsider Ownership
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
17.40%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.30%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
14.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
6034.98 million28.89 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32053.14 million51.92 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900389.08 million346.28 millionOptionable
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
408.57 million7.29 millionN/A

Recent News About These Companies

Sanuwave (SNWV) Q2 Revenue Jumps 42%
Sanuwave Announces Q2 FY2025 Financial Results
SANUWAVE Health, Inc. (SNWV): A Bull Case Theory
Sanuwave Announces Q1 FY2025 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Delcath Systems stock logo

Delcath Systems NASDAQ:DCTH

$11.02 +0.14 (+1.29%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$10.86 -0.16 (-1.44%)
As of 08/29/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$2.37 -0.09 (-3.66%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$2.36 -0.01 (-0.25%)
As of 08/29/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Moderna stock logo

Moderna NASDAQ:MRNA

$24.09 -0.38 (-1.55%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$24.16 +0.07 (+0.29%)
As of 08/29/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Sanuwave Health stock logo

Sanuwave Health NASDAQ:SNWV

$41.64 -0.80 (-1.89%)
As of 08/29/2025 04:00 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.